PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions

leverage+ non leverage

Last updated Mar 2, 2024

combination of leverage and non leverage Nasdaq and Tech

Asset Allocation


TQQQ 20%QQQ 20%FNGU 20%XLK 15%SOXX 15%SOXL 10%EquityEquity
PositionCategory/SectorWeight
TQQQ
ProShares UltraPro QQQ
Leveraged Equities, Leveraged

20%

QQQ
Invesco QQQ
Large Cap Blend Equities

20%

FNGU
MicroSectors FANG+™ Index 3X Leveraged ETN
Leveraged Equities, Leveraged

20%

XLK
Technology Select Sector SPDR Fund
Technology Equities

15%

SOXX
iShares PHLX Semiconductor ETF
Technology Equities

15%

SOXL
Direxion Daily Semiconductor Bull 3x Shares
Leveraged Equities, Leveraged

10%

S&P 500

Performance

The chart shows the growth of an initial investment of $10,000 in leverage+ non leverage, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Quarterly


0.00%100.00%200.00%300.00%400.00%500.00%OctoberNovemberDecember2024FebruaryMarch
497.16%
80.94%
leverage+ non leverage
Benchmark (^GSPC)
Portfolio components

The earliest data available for this chart is Jan 23, 2018, corresponding to the inception date of FNGU

Returns


Year-To-Date1 month6 months1 year5 years (annualized)10 years (annualized)
^GSPC
S&P 500
7.70%6.01%13.76%29.03%12.89%10.63%
leverage+ non leverage25.30%18.30%49.48%142.36%44.02%N/A
TQQQ
ProShares UltraPro QQQ
24.52%15.83%50.46%173.67%37.83%36.75%
XLK
Technology Select Sector SPDR Fund
9.50%5.29%20.13%51.70%25.62%20.86%
SOXL
Direxion Daily Semiconductor Bull 3x Shares
53.92%48.94%101.99%210.37%41.74%43.93%
SOXX
iShares PHLX Semiconductor ETF
18.01%15.43%33.52%63.55%31.15%25.76%
QQQ
Invesco QQQ
8.81%5.62%18.48%49.72%21.50%18.26%
FNGU
MicroSectors FANG+™ Index 3X Leveraged ETN
46.76%30.05%86.90%349.74%54.47%N/A

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
20243.62%15.53%
2023-6.35%-11.91%-6.52%26.55%14.43%

Sharpe Ratio

The current leverage+ non leverage Sharpe ratio is 3.76. A Sharpe ratio of 3.0 or higher is considered excellent.

0.002.004.003.76

The Sharpe ratio of leverage+ non leverage is in the top 25%, it signifies superior risk-adjusted performance. This means that for the level of risk undertaken, the portfolio is generating impressive returns compared to most others.


Rolling 12-month Sharpe Ratio0.001.002.003.004.00OctoberNovemberDecember2024FebruaryMarch
3.76
2.44
leverage+ non leverage
Benchmark (^GSPC)
Portfolio components

Dividend yield

leverage+ non leverage granted a 0.55% dividend yield in the last twelve months.


TTM20232022202120202019201820172016201520142013
leverage+ non leverage0.55%0.66%0.72%0.28%0.38%0.56%0.78%0.52%1.12%0.66%0.78%0.63%
TQQQ
ProShares UltraPro QQQ
1.01%1.26%0.57%0.00%0.00%0.06%0.11%0.00%0.00%0.01%0.03%0.00%
XLK
Technology Select Sector SPDR Fund
0.69%0.76%1.04%0.65%0.92%1.16%1.60%1.37%1.74%1.79%1.75%1.70%
SOXL
Direxion Daily Semiconductor Bull 3x Shares
0.33%0.51%1.07%0.04%0.05%0.38%1.30%0.09%4.84%0.00%0.00%0.00%
SOXX
iShares PHLX Semiconductor ETF
0.66%0.78%1.26%0.64%0.81%1.23%1.37%0.90%1.08%1.29%1.56%1.18%
QQQ
Invesco QQQ
0.57%0.62%0.80%0.43%0.55%0.74%0.91%0.84%1.06%0.99%1.41%1.01%
FNGU
MicroSectors FANG+™ Index 3X Leveraged ETN
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Expense Ratio

The leverage+ non leverage has a high expense ratio of 0.61%, indicating higher-than-average management fees. Below you can find the expense ratios of portfolio funds side-by-side and effortlessly compare their relative costs.


0.50%1.00%1.50%2.00%0.99%
0.50%1.00%1.50%2.00%0.95%
0.50%1.00%1.50%2.00%0.46%
0.50%1.00%1.50%2.00%0.20%
0.50%1.00%1.50%2.00%0.13%

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for positions. Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
^GSPC
S&P 500
2.44
leverage+ non leverage
3.76
TQQQ
ProShares UltraPro QQQ
4.01
XLK
Technology Select Sector SPDR Fund
3.19
SOXL
Direxion Daily Semiconductor Bull 3x Shares
2.83
SOXX
iShares PHLX Semiconductor ETF
2.44
QQQ
Invesco QQQ
3.28
FNGU
MicroSectors FANG+™ Index 3X Leveraged ETN
5.26

Asset Correlations Table

The table below displays the correlation coefficients between the individual components of the portfolio, the entire portfolio, and the chosen benchmark.

FNGUSOXLSOXXXLKQQQTQQQ
FNGU1.000.770.770.850.910.91
SOXL0.771.001.000.870.850.85
SOXX0.771.001.000.870.850.85
XLK0.850.870.871.000.970.97
QQQ0.910.850.850.971.001.00
TQQQ0.910.850.850.971.001.00

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-40.00%-30.00%-20.00%-10.00%0.00%OctoberNovemberDecember2024FebruaryMarch00
leverage+ non leverage
Benchmark (^GSPC)
Portfolio components

Worst Drawdowns

The table below displays the maximum drawdowns of the leverage+ non leverage. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the leverage+ non leverage was 68.68%, occurring on Nov 3, 2022. Recovery took 315 trading sessions.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-68.68%Nov 22, 2021240Nov 3, 2022315Feb 7, 2024555
-55.99%Feb 20, 202022Mar 20, 202073Jul 6, 202095
-43.43%Aug 30, 201880Dec 24, 201881Apr 23, 2019161
-28.17%May 6, 201920Jun 3, 2019107Nov 1, 2019127
-26.18%Feb 17, 202114Mar 8, 202178Jun 28, 202192

Volatility Chart

The current leverage+ non leverage volatility is 12.70%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%OctoberNovemberDecember2024FebruaryMarch
12.70%
3.47%
leverage+ non leverage
Benchmark (^GSPC)
Portfolio components
0 comments